NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.94 +0.46 (+0.59%) GOLD FUTURES
2,321.60 -9.60 (-0.41%) DOW
38,941.08 +88.81 (+0.23%) Bitcoin GBP
50,617.93 +51.94 (+0.10%)
Protalix BioTherapeutics, Inc. (PLX)
| Previous close | 1.1100 |
| Open | 1.1300 |
| Bid | 1.1500 x 800 |
| Ask | 1.1600 x 1300 |
| Day's range | 1.1200 - 1.1600 |
| 52-week range | 1.0700 - 3.1300 |
| Volume | |
| Avg. volume | 388,067 |
| Market cap | 84.68M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 12.83 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
- PR Newswire
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2023, and provided a business update.
- PR Newswire
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.
